search
Back to results

Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855

Primary Purpose

Symptomatic Neurogenic Orthostatic Hypertension, nOH

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Ampreloxetine
Sponsored by
Theravance Biopharma
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Symptomatic Neurogenic Orthostatic Hypertension focused on measuring Symptomatic neurogenic orthostatic hypertension, hepatic impairment

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

All Subjects:

  • has a body mass index (BMI) of 19 to 40 kg/m2, inclusive, and weight of at least 55 kg.
  • clinical labs within normal ranges
  • creatinine clearance of >70 mL/min
  • women must be non-pregnant and non-lactating, male and females must agree to highly effective methods of contraception
  • additional criteria apply

Subjects with Impaired Hepatic Function additional criteria:

  • Subject has mild (Child-Pugh Class A [5 to 6 points]), moderate (Child-Pugh Class B [7 to 9 points]), or severe (Child-Pugh Class C [10-15 points]) liver disease
  • has stable hepatic impairment defined as no clinically significant change in disease status within the last 30 days
  • must be on a stable dose of medication and/or treatment regimen at least 30 days before dosing
  • Additional inclusion criteria apply

Exclusion Criteria:

Subjects with normal hepatic function:

  • history of reactions or hypersensitivity to ampreloxetine or known intolerance to other norepinephrine reuptake inhibitors (NRI) or serotonin norepinephrine reuptake inhibitors (SNRI).
  • personal or family history of congenital long QT syndrome
  • history of untreated closed angle glaucoma
  • history of orthostatic hypotension or orthostatic tachycardia or a history of dizziness, lightheadedness or fainting, or a feeling of blacking out upon standing
  • has used nephrotoxic or hepatotoxic medications 30 days before Day-2
  • routinely uses more than 2 grams of acetaminophen daily
  • has used tobacco-containing products (e.g., cigarettes, cigars, chewing tobacco, snuff, e cigarettes, vaporizers) within 3 months before Screening or has a positive cotinine result at Screening or Day -2
  • used any CYP1A2 inhibitor or inducer within 7 days or 5 half lives, whichever is longer, prior to ampreloxetine dosing or requires concomitant use
  • has used monoamine oxidase inhibitors (MAO-I) within 7 days or 5 half lives, whichever is longer, prior to ampreloxetine dosing or requires concomitant use
  • additional exclusion criteria apply

Subjects with impaired hepatic function additional criteria:

  • has severe ascites that could potentially interfere with respiratory function
  • current severe hepatic encephalopathy
  • history of liver transplantation, hepatocellular carcinoma, or acute liver disease
  • has biliary liver cirrhosis
  • has uncontrolled hypertension (SBP >180 mm Hg and DBP (Diastolic blood pressure) >110 mm Hg)
  • has an abnormal ECG at Screening or Day -2, including QTcF (Fridericia's corrected QT Interval) >470 msec
  • additional exclusion criteria apply

Sites / Locations

  • Theravance Biopharma Investigational Site
  • Theravance Biopharma Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

Normal Hepatic Function

Mild Hepatic Function

Moderate Hepatic Function

Severe Hepatic Function

Arm Description

Ampreloxetine Dose A single dose administration to subjects with normal hepatic function

Ampreloxetine Dose A single dose administration to subjects with mild hepatic impairment

Ampreloxetine Dose A single dose administration to subjects with moderate hepatic impairment

Ampreloxetine Dose A single dose administration to subjects with severe hepatic impairment

Outcomes

Primary Outcome Measures

Plasma AUC0-t
Estimation of Area under the concentration-time curve, from time zero to the last measured time point
Plasma AUC0-inf
Estimation of AUC from time zero extrapolated to infinity
Plasma Cmax
Estimation of maximum observed plasma concentration

Secondary Outcome Measures

Number of subjects with clinically significant vital sign abnormalities
Clinically significant abnormalities in vital signs will be listed and described
Number of subjects with change in C-SSRS scores
Changes in Columbia suicide severity rating scale (C-SSRS) scores will be listed and described

Full Information

First Posted
December 13, 2019
Last Updated
September 7, 2021
Sponsor
Theravance Biopharma
search

1. Study Identification

Unique Protocol Identification Number
NCT04200573
Brief Title
Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855
Official Title
A Phase 1, Open-Label, Single Dose Study to Evaluate the Pharmacokinetics of Ampreloxetine Following a Single-dose in Subjects With Mild, Moderate, and Severe Hepatic Impairment and in Matching Healthy Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
September 2021
Overall Recruitment Status
Completed
Study Start Date
January 13, 2020 (Actual)
Primary Completion Date
August 19, 2021 (Actual)
Study Completion Date
August 19, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Theravance Biopharma

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
An open-label study to characterize the effects of mild, moderate, and severe Hepatic Impairment (HI) on the pharmacokinetics (PK) of ampreloxetine following a single oral dose in comparison with healthy volunteers with normal hepatic function.
Detailed Description
This is a multicenter, non-randomized, open label, parallel group, single dose, 2-part study being conducted in adult subjects with mild, moderate, or severe HI (Child-Pugh Class A, B, and C), and in matching healthy subjects. The healthy matching group will be comparable to the corresponding hepatic impairment groups by matching subjects by weight (±20% of group mean), age (±10 years of group mean), and sex (equal ratios across groups). The study will be conducted in two sequential parts: In Part A, following a 28-day screening period, 6 subjects each with mild or moderate HI and 6 matching healthy subjects who meet eligibility criteria will be enrolled and administered a single Dose A (Day 1). In Part B, following a 28-day screening period, 6 subjects with severe hepatic impairment will receive a single Dose A (Day 1). Furthermore, the Sponsor may choose to enroll up to 6 additional healthy subjects in Part B to ensure matching of subjects across all groups for weight, age, and sex is maintained.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Symptomatic Neurogenic Orthostatic Hypertension, nOH
Keywords
Symptomatic neurogenic orthostatic hypertension, hepatic impairment

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
31 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Normal Hepatic Function
Arm Type
Experimental
Arm Description
Ampreloxetine Dose A single dose administration to subjects with normal hepatic function
Arm Title
Mild Hepatic Function
Arm Type
Experimental
Arm Description
Ampreloxetine Dose A single dose administration to subjects with mild hepatic impairment
Arm Title
Moderate Hepatic Function
Arm Type
Experimental
Arm Description
Ampreloxetine Dose A single dose administration to subjects with moderate hepatic impairment
Arm Title
Severe Hepatic Function
Arm Type
Experimental
Arm Description
Ampreloxetine Dose A single dose administration to subjects with severe hepatic impairment
Intervention Type
Drug
Intervention Name(s)
Ampreloxetine
Other Intervention Name(s)
TD-9855
Intervention Description
The study drug will be administered orally as a single Dose A tablet
Primary Outcome Measure Information:
Title
Plasma AUC0-t
Description
Estimation of Area under the concentration-time curve, from time zero to the last measured time point
Time Frame
Plasma AUC0-t will be measured Day 1 to Day 15
Title
Plasma AUC0-inf
Description
Estimation of AUC from time zero extrapolated to infinity
Time Frame
Plasma AUC0-inf will be measured from Day 1 to Day 15
Title
Plasma Cmax
Description
Estimation of maximum observed plasma concentration
Time Frame
up to Day 21
Secondary Outcome Measure Information:
Title
Number of subjects with clinically significant vital sign abnormalities
Description
Clinically significant abnormalities in vital signs will be listed and described
Time Frame
up to Day 21
Title
Number of subjects with change in C-SSRS scores
Description
Changes in Columbia suicide severity rating scale (C-SSRS) scores will be listed and described
Time Frame
up to Day 21

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: All Subjects: has a body mass index (BMI) of 19 to 40 kg/m2, inclusive, and weight of at least 55 kg. clinical labs within normal ranges creatinine clearance of >70 mL/min women must be non-pregnant and non-lactating, male and females must agree to highly effective methods of contraception additional criteria apply Subjects with Impaired Hepatic Function additional criteria: Subject has mild (Child-Pugh Class A [5 to 6 points]), moderate (Child-Pugh Class B [7 to 9 points]), or severe (Child-Pugh Class C [10-15 points]) liver disease has stable hepatic impairment defined as no clinically significant change in disease status within the last 30 days must be on a stable dose of medication and/or treatment regimen at least 30 days before dosing Additional inclusion criteria apply Exclusion Criteria: Subjects with normal hepatic function: history of reactions or hypersensitivity to ampreloxetine or known intolerance to other norepinephrine reuptake inhibitors (NRI) or serotonin norepinephrine reuptake inhibitors (SNRI). personal or family history of congenital long QT syndrome history of untreated closed angle glaucoma history of orthostatic hypotension or orthostatic tachycardia or a history of dizziness, lightheadedness or fainting, or a feeling of blacking out upon standing has used nephrotoxic or hepatotoxic medications 30 days before Day-2 routinely uses more than 2 grams of acetaminophen daily has used tobacco-containing products (e.g., cigarettes, cigars, chewing tobacco, snuff, e cigarettes, vaporizers) within 3 months before Screening or has a positive cotinine result at Screening or Day -2 used any CYP1A2 inhibitor or inducer within 7 days or 5 half lives, whichever is longer, prior to ampreloxetine dosing or requires concomitant use has used monoamine oxidase inhibitors (MAO-I) within 7 days or 5 half lives, whichever is longer, prior to ampreloxetine dosing or requires concomitant use additional exclusion criteria apply Subjects with impaired hepatic function additional criteria: has severe ascites that could potentially interfere with respiratory function current severe hepatic encephalopathy history of liver transplantation, hepatocellular carcinoma, or acute liver disease has biliary liver cirrhosis has uncontrolled hypertension (SBP >180 mm Hg and DBP (Diastolic blood pressure) >110 mm Hg) has an abnormal ECG at Screening or Day -2, including QTcF (Fridericia's corrected QT Interval) >470 msec additional exclusion criteria apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Monitor
Organizational Affiliation
Theravance Biopharma
Official's Role
Study Director
Facility Information:
Facility Name
Theravance Biopharma Investigational Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33014
Country
United States
Facility Name
Theravance Biopharma Investigational Site
City
Orlando
State/Province
Florida
ZIP/Postal Code
32809
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.

Learn more about this trial

Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855

We'll reach out to this number within 24 hrs